Dihydropyrimidine dehydrogenase phenotyping using pretreatment uracil: a note of caution based on a large prospective clinical study

Autor: With, M. de, Knikman, J., Man, F.M. de, Lunenburg, C.A.T.C., Henricks, L.M., Kuilenburg, A.B.P. van, Maring, J.G., Staveren, M.C. van, Vries, N. de, Rosing, H., Beijnen, J.H., Pluim, D., Modak, A., Imholz, A.L.T., Schaik, R.H.N. van, Schellens, J.H.M., Gelderblom, H., Cats, A., Guchelaar, H.J., Mathijssen, R.H.J., Swen, J.J., Meulendijks, D.

Publikováno v: Clinical Pharmacology & Therapeutics, 112(1), 62-68. WILEY
Clinical Pharmacology and Therapeutics, 112(1), 62-68. Wiley-Blackwell
Clinical pharmacology and therapeutics, 112(1), 62-68. Wiley-Blackwell

In clinical practice, 25–30% of the patients treated with fluoropyrimidines experience severe fluoropyrimidine-related toxicity. Extensively clinically validated DPYD genotyping tests are available to identify patients at risk of severe toxicity du

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f5e872538b1e1ef4d8d5d9938c0f590e
http://hdl.handle.net/1887/3515269

Dihydropyrimidine Dehydrogenase Phenotyping Using Pretreatment Uracil: A Note of Caution Based on a Large Prospective Clinical Study.

Autor: de With M; Department of Medical Oncology, Erasmus Medical Center Cancer Institute, Rotterdam, The Netherlands.; Department of Clinical Chemistry, Erasmus Medical Center, Rotterdam, The Netherlands., Knikman J; Division of Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., de Man FM; Department of Medical Oncology, Erasmus Medical Center Cancer Institute, Rotterdam, The Netherlands., Lunenburg CATC; Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands., Henricks LM; Division of Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Division of Medical Oncology, Department of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Clinical Chemistry and Laboratory Medicine, Leiden University Medical Center, Leiden, The Netherlands., van Kuilenburg ABP; Laboratory Genetic Metabolic Diseases, Department of Clinical Chemistry, Amsterdam UMC, Cancer Center Amsterdam, Amsterdam Gastroenterology Endocrinology Metabolism, University of Amsterdam, Amsterdam, The Netherlands., Maring JG; Department of Pharmacy, Isala Hospital, Zwolle, The Netherlands.; Isala Diaconessen Hospital, Meppel, The Netherlands., van Staveren MC; Department of Clinical Pharmacy and Toxicology, Treant Healthgroup, Scheper Hospital, Emmen, The Netherlands., de Vries N; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Rosing H; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Beijnen JH; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Division of Pharmacoepidemiology and Clinical Pharmacology, Department of Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, The Netherlands., Pluim D; Division of Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Modak A; Cambridge Isotope Laboratories, Tewksbury, Massachusetts, USA., Imholz ALT; Department of Internal Medicine, Deventer Hospital, Deventer, The Netherlands., van Schaik RHN; Department of Clinical Chemistry, Erasmus Medical Center, Rotterdam, The Netherlands., Schellens JHM; Division of Pharmacoepidemiology and Clinical Pharmacology, Department of Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, The Netherlands., Gelderblom H; Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands., Cats A; Division of Medical Oncology, Department of Gastrointestinal Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Guchelaar HJ; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands.; Leiden Network for Personalised Therapeutics (LNPT), Leiden, The Netherlands., Mathijssen RHJ; Department of Medical Oncology, Erasmus Medical Center Cancer Institute, Rotterdam, The Netherlands., Swen JJ; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands.; Leiden Network for Personalised Therapeutics (LNPT), Leiden, The Netherlands., Meulendijks D; Division of Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Division of Medical Oncology, Department of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Late Development Oncology, AstraZeneca, Cambridge, UK.

Publikováno v: Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2022 Jul; Vol. 112 (1), pp. 62-68. Date of Electronic Publication: 2022 May 04.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Case report: A case of severe capecitabine toxicity due to confirmed in trans compound heterozygosity of a common and rare DPYD variant.

Autor: de Haar-Holleman, Amy, Cortoos, Pieter-Jan, Vlaeminck, Jelle, Van Landuyt, Paulien, Steurbaut, Stephane, Vaeyens, Freya, Haufroid, Vincent

Publikováno v: Frontiers in Pharmacology; 2024, p1-6, 6p

Dihydropyrimidine dehydrogenase (DPD) genotype and phenotype among Danish cancer patients: prevalence and correlation between DPYD-genotype variants and P-uracil concentrations.

Autor: Paulsen, Niels Herluf^1,2, Qvortrup, Camilla³, Vojdeman, Fie Juhl⁴, Plomgaard, Peter^5,6, Andersen, Stig Ejdrup⁷, Ramlov, Anne⁸, Bertelsen, Birgitte⁹, Rossing, Maria^6,10, Nielsen, Claus Gyrup¹¹, Hoffmann-Lücke, Elke^12,13, Greibe, Eva^12,13, Spangsberg Holm, Hanne¹⁴, Nielsen, Heidi Hvid¹⁵, Lolas, Ihab Bishara Yousef¹⁶, Madsen, Jonna Skov^17,18, Bergmann, Marianne Lerbaek¹⁷, Mørk, Morten^11,16, Fruekilde, Palle B. Nielsen¹⁹, Bøttger, Pernille^17,18, Petersen, Peter Clausager²⁰

Publikováno v: Acta Oncologica. Nov2022, Vol. 61 Issue 11, p1400-1405. 6p. 1 Chart, 2 Graphs.